Abstract
Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Current Drug Metabolism
Title:Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Volume: 13 Issue: 10
Author(s): Mustapha Cherkaoui-Malki, Sailesh Surapureddi, Hammam I. El Hajj, Joseph Vamecq and Pierre Andreoletti
Affiliation:
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Abstract: Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Export Options
About this article
Cite this article as:
Cherkaoui-Malki Mustapha, Surapureddi Sailesh, I. El Hajj Hammam, Vamecq Joseph and Andreoletti Pierre, Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation, Current Drug Metabolism 2012; 13 (10) . https://dx.doi.org/10.2174/138920012803762765
DOI https://dx.doi.org/10.2174/138920012803762765 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products
Recent Patents on Food, Nutrition & Agriculture Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Advances in Fish Cytokine Biology Give Clues to the Evolution of a Complex Network
Current Pharmaceutical Design Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells
Recent Patents on Anti-Cancer Drug Discovery Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
Current Medicinal Chemistry - Anti-Cancer Agents Self-Renewal Versus Differentiation in Hematopoietic Stem and Progenitor Cells: A Focus on Asymmetric Cell Divisions
Current Stem Cell Research & Therapy